Introduction
chronic myeloid leukemia, CML-CP
CHRONIC MYELOID LEUKEMIA
The treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior ATP-competitive tyrosine kinase inhibitors (TKIs) is poorly established owing to a lack of prospective studies in this setting [Asciminib is the first BCR::ABL1 inhibitor to Primary (week 24) efficacy and safety results from ASCEMBL in patients with CML-CP after ≥2 prior TKIs were reported previously [After 1 year (48 weeks) of follow-up, asciminib continued to show increasing efficacy benefit vs bosutinib, with no new or worsening safety findings as compared with the primary analysis [